X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Insider Mark Baldry Sells 29,159 Shares of Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) insider Mark Baldry sold 29,159 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $13,121.55. Following the completion of the transaction, the insider now directly owns 94,123 shares in the company, valued at approximately $42,355.35. This represents a 23.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ XFOR opened at $0.49 on Tuesday. X4 Pharmaceuticals, Inc. has a one year low of $0.26 and a one year high of $1.60. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The business has a fifty day simple moving average of $0.55 and a 200 day simple moving average of $0.61. The firm has a market capitalization of $83.84 million, a price-to-earnings ratio of -5.46 and a beta of 0.14.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in XFOR. Verition Fund Management LLC bought a new stake in X4 Pharmaceuticals in the third quarter valued at about $30,000. SG Americas Securities LLC acquired a new stake in X4 Pharmaceuticals during the third quarter valued at approximately $37,000. XTX Topco Ltd bought a new stake in shares of X4 Pharmaceuticals in the 2nd quarter valued at approximately $65,000. Rhumbline Advisers raised its holdings in shares of X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after buying an additional 23,831 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of X4 Pharmaceuticals by 103.4% during the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after buying an additional 126,296 shares during the period. 72.03% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

XFOR has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Tuesday, January 14th. Stifel Nicolaus cut their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.